Theranexus SA
Research Theranexus SA (ALTHX) on Bullrun: market cap EUR 49.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALTHX
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 49.10M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 3.00M
- Free cash flow-EUR 1.08M
Valuation Snapshot
latest market cap is EUR 49.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 3.00M | -EUR 1.08M | n/a | n/a | EUR 740.98K | EUR 2.88M | EUR 2.90M |
| FY2024 | EUR 0 | -EUR 1.77M | -EUR 3.40M | n/a | -0.22 | EUR 714.31K | EUR 2.87M | -EUR 1.66M |
| FY2023 | EUR 0 | -EUR 6.83M | -EUR 6.45M | n/a | -0.87 | EUR 1.20M | EUR 3.64M | EUR 2.22M |
| FY2022 | EUR 0 | -EUR 6.57M | -EUR 5.45M | n/a | -1.24 | EUR 2.10M | EUR 4.89M | EUR 5.73M |
| FY2021 | n/a | n/a | n/a | n/a | -1.63 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | EUR 49.10M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Theranexus SA's market cap?
Theranexus SA's market capitalization is EUR 49.10M.
What does Theranexus SA do?
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.